12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trans sodium crocetinate regulatory update

Diffusion said FDA granted Orphan Drug designation for its TSC to treat metastatic brain cancer. Diffusion plans to...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >